Skip to main content

Table 1 Patient characteristics

From: Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

 

All, n = 148

High GNRI, n = 110

Low GNRI, n = 38

p-value

Age, years

65 (36–84)

65 (36–84)

67 (40–79)

0.175

Sex, men

109 (73.6)

30 (27.3)

9 (23.7)

0.831

Smoking status, ever-smoker

111 (75.0)

80 (72.7)

31 (81.6)

0.385

ECOG-PS, 0/1/ ≥ 2

90 (60.8)/42 (28.3)/16 (10.8)

77 (70.0)/29 (23.4)/4 (3.6)

13 (34.2)/13 (34.2)/12 (31.6)

 < 0.001

Body mass index, kg/m2

21.9 (13.7–30.5)

22.7 (13.7–30.5)

18.5 (14.2–25.0)

 < 0.001

Serum albumin (g/dL)

3.7 (2.1–4.9)

3.9 (2.5–4.9)

2.9 (2.1–3.8)

 < 0.001

GNRI

100.6 (56.6–124.6)

105.0 (92.5–124.6)

82.0 (55.6–90.5)

 < 0.001

Stage, IIIb/IV/recurrence

20 (13.5)/127 (85.8)/1 (0.7)

15 (13.6)/94 (85.5)/1 (0.9)

5 (13.2)/33 (86.8)/0 (0)

1.000

Pathology, squamous/non-squamous

39 (26.4)/109 (73.6)

26 (23.6)/84 (76.4)

13 (34.2)/25 (65.8)

0.208

EGFR mutation, positive/wild-type/unknown

16 (10.8)/101 (68.2)/31 (20.9)

15 (13.6)/71 (64.6)/24 (21.8)

1 (2.6)/30 (79.0)/7 (18.4)

0.120

ALK fusion gene, positive/wild-type/unknown

1 (0.7)/73 (49.3)/74 (50.0)

1 (0.9)/58 (52.7)/51 (46.4)

0 (0)/15 (39.5)/23 (60.5)

0.396

Comorbidities

    

Diabetes

24 (16.2)

20 (18.2)

4 (10.5)

0.319

Chronic pulmonary diseases

22 (14.9)

14 (12.7)

8 (21.1)

0.289

Myocardial infarction

6 (4.1)

5 (4.6)

1 (2.6)

1.000

Peripheral vascular diseases

3 (2.0)

1 (0.9)

2 (5.3)

0.162

Collagen diseases

4 (2.7)

2 (1.8)

2 (5.3)

0.272

Solid tumors

5 (3.4)

3 (2.7)

2 (5.3)

0.603

Liver diseases

4 (2.7)

1 (0.9)

3 (7.9)

0.052

Charlson comorbidity index

0 (0–3)

0 (0–3)

0 (0–3)

0.300

Chemotherapy regimens

   

0.273

Carboplatin/(nab-)paclitaxel ± bevacizumab

54 (36.5)

41 (37.3)

13 (34.2)

 

Carboplatin/pemetrexed ± bevacizumab

45 (30.4)

34 (30.9)

11 (29.0)

 

Cisplatin/pemetrexed ± bevacizumab

16 (10.8)

14 (12.7)

2 (5.3)

 

Other cisplatin-based therapy

20 (13.5)

10 (9.1)

3 (7.9)

 

Other carboplatin-based therapy

13 (8.8)

11 (10.0)

9 (23.7)

 

Treatment year, 2000–2010/2011–2020

61 (41.2)/87 (58.8)

44 (40.0)/66 (60.0)

17 (44.7)/21 (55.3)

0.703

  1. Data are expressed as the median (range) or number (%). The p values indicate comparisons between high and low GNRI group
  2. ALK anaplastic lymphoma kinase, ECOG-PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, GNRI geriatric nutritional risk index
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us